ZyVersa Therapeutics Files Definitive Proxy Statement

TL;DR

ZyVersa (ZYVR) filed its DEF 14A proxy statement on Jan 17, 2025. Standard shareholder disclosure.

AI Summary

ZyVersa Therapeutics, Inc. filed a Definitive Proxy Statement (DEF 14A) on January 17, 2025. The filing concerns the company's proxy materials, indicating it is a standard disclosure for shareholders regarding company matters. ZyVersa Therapeutics, Inc. is incorporated in Delaware and has its principal executive offices in Weston, Florida.

Why It Matters

This filing is a routine disclosure required for public companies, providing shareholders with information necessary to vote on company matters.

Risk Assessment

Risk Level: low — This is a routine administrative filing (DEF 14A) and does not contain new material financial or operational information.

Key Players & Entities

• ZyVersa Therapeutics, Inc. (company) — Registrant
• 20250117 (date) — Filing Date
• DEF 14A (document_type) — Filing Type
• Larkspur Health Acquisition Corp. (company) — Former Company Name

FAQ

Key Financial Figures

• $15,000 — LLC will receive a fee of approximately $15,000, as well as reimbursement for certain c

Filing Documents

• formdef14a.htm (DEF 14A) — 309KB
• proxy_001.jpg (GRAPHIC) — 358KB
• proxy_002.jpg (GRAPHIC) — 307KB
• 0001493152-25-002752.txt ( ) — 1227KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 12 HOUSEHOLDING OF PROXY MATERIALS 14 OTHER MATTERS 15 Annex A - Form of Series A-2 Warrant A-1 ZYVERSA THERAPEUTICS, INC. 2200 N. Commerce Parkway, Suite 208 Weston, Florida 33326 PROXY FOR THE 2025 SPECIAL MEETING OF STOCKHOLDERS March 4, 2025 QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Who is ZyVersa Therapeutics, Inc.? ZyVersa Therapeutics, Inc. (the “Company,” “ZyVersa,” “we,” “us,” or “our”) is a clinical stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. Our mission is to develop drugs that optimize health outcomes and improve patients’ quality of life. We have two proprietary globally licensed drug development platforms, each of which was discovered by research scientists at the University of Miami, Miller School of Medicine (the “University of Miami” or “University”). These development platforms are: Cholesterol Efflux Mediator TM VAR 200 (2-hydroxypropyl-beta-cyclodextrin or “2HPβCD”) is an injectable drug in clinical development for treatment of renal diseases. VAR 200 was licensed from L&F Research LLC on December 15, 2015. L&F Research was founded by the University of Miami research scientists who discovered the use of VAR 200 for renal diseases. Inflammasome ASC Inhibitor IC 100 is a humanized monoclonal antibody in preclinical development for treatment of inflammatory conditions. IC 100 was licensed from InflamaCore, LLC on April 18, 2019. InflamaCore, LLC was founded by the University of Miami research scientists who invented IC 100. We believe that each of our product candidates has the potential to treat numerous indications in their respective therapeutic areas. Our strategy is to focus on indic

Business

Business Combination On December 12, 2022 (the “Closing Date”), we consummated the previously announced Business Combination (as defined below) pursuant to the terms of that certain Business Combination Agreement (the “Business Combination Agreement”), by and among ZyVersa Therapeutics, Inc., a Florida corporation (“Old ZyVersa”), the representative of Old ZyVersa’s shareholders named therein (the “Securityholder Representative”), Larkspur Health Acquisition Corp., a Delaware corporation (“Larkspur”), and Larkspur Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Larkspur (“Merger Sub”). Pursuant to the terms of the Business Combination Agreement (and upon all other conditions of the Business Combination Agreement being satisfied or waived), on the Closing Date of the Business Combination and transactions contemplated thereby (the “Business Combination”), (i) Larkspur changed its name to “ZyVersa Therapeutics, Inc.”, a Delaware corporation (the “Company”) and (ii) Merger Sub merged with and into Old ZyVersa (the “Merger”), with Old ZyVersa as the surviving company in the Merger and, after giving effect to such Merger, Old ZyVersa became a wholly-owned subsidiary of the Company. Prior to the completion of the Business Combination, the Company was a shell company. Following the Business Combination, the business of Old ZyVersa is the business of the Company. The Company was incorporated in the State of Delaware on March 17, 2021 and its subsidiary, Old ZyVersa, was incorporated on March 11, 2014. Larkspur Merger Sub, Inc. was incorporated in the State of Delaware on July 13, 2022. Our principal executive offices are located at 2200 North Commerce Parkway, Suite 208, Weston, Florida 33326, and our telephone number is (754) 231-1688. Our website address is http://www.zyversa.com. The information contained on or otherwi

View Full Filing

View this DEF 14A filing on SEC EDGAR